TELA Bio financials
$1.24+0.81%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.3M | $19.1M | $20.9M | $20.7M | $20.2M | $18.5M | $17.6M | $19.0M | $16.1M | $16.6M | $17.0M | $15.1M |
| Gross profit | $13.9M | $12.5M | $13.8M | $14.0M | $14.1M | $12.5M | $11.2M | $12.9M | $11.2M | $11.3M | $11.6M | $10.4M |
| Gross margin | 72.3% | 65.7% | 65.9% | 67.5% | 69.8% | 67.6% | 63.6% | 67.8% | 69.4% | 68.3% | 68.4% | 69.0% |
| Operating income | -$9.3M | -$10.5M | -$6.6M | -$7.6M | -$9.1M | -$10.5M | -$8.4M | -$9.4M | -$11.6M | -$12.4M | -$12.3M | -$10.2M |
| Net income | -$11.3M | -$12.3M | -$9.0M | -$8.6M | -$9.9M | -$11.3M | -$9.2M | -$10.4M | -$12.6M | -$5.7M | -$12.9M | -$11.0M |
| Net margin | −58.4% | −64.4% | −43.3% | −41.6% | −49.1% | −60.8% | −52.2% | −54.7% | −78.3% | −34.1% | −75.8% | −72.8% |
| Diluted EPS | $-0.20 | $-0.21 | $-0.17 | $-0.19 | $-0.22 | $-0.25 | $-0.23 | $-0.42 | $-0.51 | $-0.23 | $-0.52 | $-0.45 |
| EBITDA | -$9.0M | -$10.3M | -$6.4M | -$7.3M | -$8.8M | -$10.2M | -$8.1M | -$9.1M | -$11.3M | -$12.2M | -$12.1M | -$10.0M |
| Operating cash flow | -$9.4M | -$11.2M | -$4.9M | -$5.7M | -$7.9M | -$9.7M | -$7.5M | -$9.0M | -$10.7M | -$14.4M | -$11.1M | -$7.0M |
| Free cash flow | -$9.4M | -$11.3M | -$5.0M | -$5.9M | -$8.0M | -$9.8M | -$7.8M | -$9.1M | -$11.0M | -$14.7M | -$11.3M | -$7.1M |
| Diluted shares | 57.4M | 57.3M | 51.7M | 45.4M | 45.4M | 45.3M | 40.2M | 24.7M | 24.7M | 24.6M | 24.6M | 24.5M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $30.4M | $39.5M | $50.8M | $29.7M | $35.0M | $42.8M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $56.1M | $55.9M | $55.7M | $41.5M | $41.4M | $41.3M |
| Total assets | $59.7M | $69.9M | $81.4M | $61.6M | $67.5M | $77.3M |
| Total liabilities | $75.6M | $75.1M | $75.1M | $60.0M | $58.4M | $59.1M |
| Shareholders' equity | -$15.9M | -$5.2M | $6.3M | $1.6M | $9.2M | $18.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology